The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
From genes to drugs: targeted strategies for melanoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Somatic Activation of KIT in Distinct Subtypes of Melanoma
Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,616
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationShimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citationRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Self-citationDhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
MITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169
Self-citationRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
Self-citationBrichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Coulie, P. G., Brichard, V, Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.35 · Cited by 903
KIT as a Therapeutic Target in Metastatic Melanoma
Carvajal, R. D. (2011) · JAMA · doi:10.1001/jama.2011.746 · Cited by 888
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Shen, Z., Reznikoff, G., Dranoff, G., & Rock, K. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2723 · Cited by 846
Banchereau, J., Palucka, A. K., Dhodapkar, M. V., Burkeholder, S. B., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001) · PubMed · Cited by 806
McGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760
Self-citationMechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., Corless, C. L., Li, L., Li, H., Sheng, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9275 · Cited by 688
Self-citationPatton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., Berghmans, S., Mayhall, E. A., Traver, D., Fletcher, C. D. M., et al. (2005) · Current Biology · doi:10.1016/j.cub.2005.01.031 · Cited by 664
Self-citationKIT Gene Mutations and Copy Number in Melanoma Subtypes
Beadling, C., Jacobson-Dunlop, E., Hodi, F. S., Le, C., Warrick, A., Patterson, J., Town, A., Harlow, A., Cruz, F., Azar, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0575 · Cited by 646
Self-citationSorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644
Self-citationShi, H., Moriceau, G., Kong, X., Lee, M.-K., Lee, H., Koya, R. C., Ng, C., Chodon, T., Scolyer, R. A., Dahlman, K. B., et al. (2012) · Nature Communications · doi:10.1038/ncomms1727 · Cited by 640
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633
Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., et al. (1999) · Nature Medicine · doi:10.1038/13928 · Cited by 594
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., & Marais, R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.022 · Cited by 594
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 594
Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13141 · Cited by 571
Self-citationVan den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., & Boon, T. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.689 · Cited by 567
Paraiso, K. H. T., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., Wood, E., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2954 · Cited by 551
Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550
Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7636 · Cited by 548
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., & Engleman, E. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141226398 · Cited by 541
Wu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G., Price, E. R., Fisher, D. Z., & Fisher, D. E. (2000) · Genes & Development · doi:10.1101/gad.14.3.301 · Cited by 527
Self-citationA SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Bertolotto, C., Lesueur, F., Giuliano, S., Strub, T., de Lichy, M., Bille, K., Dessen, P., d’Hayer, B., Mohamdi, H., Remenieras, A., et al. (2011) · Nature · doi:10.1038/nature10539 · Cited by 526
O'Day, S. J., Maio, M., Chiarion-Sileni, V., Gajewski, T. F., Pehamberger, H., Bondarenko, I. N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 514
Bastian, B. C., LeBoit, P. E., Hamm, H., Bröcker, E.-B., & Pinkel, D. (1998) · PubMed · Cited by 513
Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513
Self-citationA novel recurrent mutation in MITF predisposes to familial and sporadic melanoma
Yokoyama, S., Woods, S. L., Boyle, G. M., Aoude, L. G., MacGregor, S., Zismann, V., Gartside, M., Cust, A. E., Haq, R., Harland, M., et al. (2011) · Nature · doi:10.1038/nature10630 · Cited by 484
Self-citationDisruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Guldberg, P., Straten, P. T., Birck, A., Ahrenkiel, V., Kirkin, A. F., & Zeuthen, J. (1997) · PubMed · Cited by 480
PTEN signaling pathways in melanoma
Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 480
Schuler-Thurner, B., Schultz, E. S., Berger, T. G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P. O., Romani, N., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012100 · Cited by 475
Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
Herman, A. E., Freeman, G. J., Mathis, D., & Benoist, C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040179 · Cited by 450
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation
Gupta, P. B., Kuperwasser, C., Brunet, J.-P., Ramaswamy, S., Kuo, W.-L., Gray, J. W., Naber, S. P., & Weinberg, R. A. (2005) · Nature Genetics · doi:10.1038/ng1634 · Cited by 439
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness
Topczewska, J. M., Postovit, L.-M., Margaryan, N. V., Sam, A., Hess, A. R., Wheaton, W. W., Nickoloff, B. J., Topczewski, J., & Hendrix, M. J. C. (2006) · Nature Medicine · doi:10.1038/nm1448 · Cited by 438
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Du, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421
Self-citationMajor Response to Imatinib Mesylate in KIT-Mutated Melanoma
Hodi, F. S., Friedlander, P., Corless, C. L., Heinrich, M. C., Mac Rae, S., Kruse, A., Jagannathan, J., Van den Abbeele, A. D., Velazquez, E. F., Demetri, G. D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0707 · Cited by 419
Self-citationChang, D. H., Osman, K., Connolly, J., Kukreja, A., Krasovsky, J., Pack, M., Hutchinson, A., Geller, M., Liu, N., Annable, R., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042592 · Cited by 415
Chambers, C. A., Sullivan, T. J., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80406-9 · Cited by 411
Mach, N., Gillessen, S., Wilson, S. B., Sheehan, C., Mihm, M. C., & Dranoff, G. (2000) · PubMed · Cited by 410
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 408
Ugurel, S., Rappl, G., Tilgen, W., & Reinhold, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.577 · Cited by 399
Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
Goel, V. K., Lazar, A. J. F., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700026 · Cited by 392
Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
Tumor‐specific shared antigenic peptides recognized by human T cells
Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E. S., Chapiro, J., Van den Eynde, B. J., Brasseur, F., & Boon, T. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18806.x · Cited by 378
Su, Z. Z., Dannull, J., Heiser, A., Yancey, D. R., Pruitt, S. K., Madden, J., Coleman, D., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2003) · PubMed · Cited by 366
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
V599EB-RAF is an Oncogene in Melanocytes
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., & Marais, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3433 · Cited by 344
Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli
Alavi, A., Hood, J. D., Frausto, R., Stupack, D. G., & Cheresh, D. A. (2003) · Science · doi:10.1126/science.1082015 · Cited by 336
Fong, L., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 323
Slingluff, C. L., Petroni, G. R., Yamshchikov, G. V., Barnd, D. L., Eastham, S., Galavotti, H., Patterson, J. W., Deacon, D. H., Hibbitts, S., Teates, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.005 · Cited by 322
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B., Egyhazi, S., Hansson, J., Wu, H., King, A. J., Van Belle, P., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 309
Self-citationSoiffer, R., Hodi, F. S., Haluska, F., Jung, K., Gillessen, S., Singer, S., Tanabe, K., Duda, R., Mentzer, S., Jaklitsch, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.005 · Cited by 305
Self-citationNKT cells — conductors of tumor immunity?
Smyth, M. J., Crowe, N. Y., Hayakawa, Y., Takeda, K., Yagita, H., & Godfrey, D. I. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00316-3 · Cited by 294
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species
Kusmartsev, S., & Gabrilovich, D. I. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0103010 · Cited by 292
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
van 't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., Schrier, P. I., & Bos, J. L. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.7.3114 · Cited by 283
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., & Marais, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002734 · Cited by 278
New insight into BRAF mutations in cancer
Dhomen, N., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
Kefford, R., Arkenau, H., Brown, M. P., Millward, M., Infante, J. R., Long, G. V., Ouellet, D., Curtis, M., Lebowitz, P. F., & Falchook, G. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8503 · Cited by 275
CpG motifs: the active ingredient in bacterial extracts?
Krieg, A. M. (2003) · Nature Medicine · doi:10.1038/nm0703-831 · Cited by 271
Young, J. W., & Inaba, K. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.7 · Cited by 269
Meier, F. (2005) · Frontiers in Bioscience · doi:10.2741/1755 · Cited by 267
King, A. J., Patrick, D. R., Batorsky, R. S., Ho, M. L., Do, H. T., Zhang, S. Y., Kumar, R., Rusnak, D. W., Takle, A. K., Wilson, D. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2554 · Cited by 257
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Wolchok, J. D., & Saenger, Y. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-2 · Cited by 250
da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
Forsberg, K., Valyi-Nagy, I., Heldin, C. H., Herlyn, M., & Westermark, B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.393 · Cited by 238
Stark, M., & Hayward, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4152 · Cited by 237
Smalley, K. S. M., Contractor, R., Haass, N. K., Kulp, A. N., Atilla-Gokcumen, G. E., Williams, D. S., Bregman, H., Flaherty, K. T., Soengas, M. S., Meggers, E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1538 · Cited by 230
Self-citationRofstad, E. K., & Halsør, E. F. (2000) · PubMed · Cited by 229
CCI‐779 in metastatic melanoma: A Phase II trial of the California Cancer Consortium
Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 227
Mullins, D. W., Sheasley, S. L., Ream, R. M., Bullock, T. N. J., Fu, Y.-X., & Engelhard, V. H. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021348 · Cited by 225
Immune Responses in 4-1BB (CD137)-Deficient Mice
Kwon, B. S., Hurtado, J. C., Lee, Z. H., Kwack, K. B., Seo, S. K., Choi, B. K., Koller, B. H., Wolisi, G., Broxmeyer, H. E., & Vinay, D. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5483 · Cited by 221
Lutzky, J., Bauer, J., & Bastian, B. C. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00475.x · Cited by 217
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
Smalley, K. S. M., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., Letrero, R., Van Belle, P., Elder, D. E., Wang, Y., Nathanson, K. L., et al. (2009) · Oncogene · doi:10.1038/onc.2008.362 · Cited by 216
Self-citationHOXB7 Constitutively Activates Basic Fibroblast Growth Factor in Melanomas
Carè, A., Silvani, A., Meccia, E., Mattia, G., Stoppacciaro, A., Parmiani, G., Peschle, C., & Colombo, M. P. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4842 · Cited by 211
BRAF alterations are associated with complex mutational profiles in malignant melanoma
Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G. D., Perrone, F., Luoni, C., Suardi, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207780 · Cited by 210
Dendritic cells: a journey from laboratory to clinic
Cerundolo, V., Hermans, I. F., & Salio, M. (2004) · Nature Immunology · doi:10.1038/ni0104-7 · Cited by 194
Sumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., & Kawakami, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207812 · Cited by 194
Lineage-specific Signaling in Melanocytes
Price, E. R., Ding, H.-F., Badalian, T., Bhattacharya, S., Takemoto, C., Yao, T.-P., Hemesath, T. J., & Fisher, D. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.17983 · Cited by 191
Self-citationPhase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
Solit, D. B., Osman, I., Polsky, D., Panageas, K. S., Daud, A., Goydos, J. S., Teitcher, J., Wolchok, J. D., Germino, F. J., Krown, S. E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1002 · Cited by 190
Sala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G. E., & Gambacorti-Passerini, C. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2001 · Cited by 188
Sebti, S. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.005 · Cited by 169
(1993) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60318-8 · Cited by 166
Ferradini, L., Mackensen, A., Genevée, C., Bosq, J., Duvillard, P., Avril, M.-F., & Hercend, T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116278 · Cited by 150
Amplification of CDK4 and MDM2 in malignant melanoma
Muthusamy, V., Hobbs, C., Nogueira, C., Cordon‐Cardo, C., McKee, P. H., Chin, L., & Bosenberg, M. W. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20310 · Cited by 148
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Jiang, X., Zhou, J., Yuen, N. K., Corless, C. L., Heinrich, M. C., Fletcher, J. A., Demetri, G. D., Widlund, H. R., Fisher, D. E., & Hodi, F. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1144 · Cited by 140
Self-citationVarker, K. A., Biber, J. L., Kefauver, C. A., Jensen, R. R., Lehman, A., Young, D. C., Wu, H. M., Lesinski, G. B., Kendra, K. L., Chen, H. X., et al. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9389-5 · Cited by 139
Soussi, T., Kato, S., Lévy, P., & Ishioka, C. (2004) · Human Mutation · doi:10.1002/humu.20114 · Cited by 139
Romano, M. F., Avellino, R., Petrella, A., Bisogni, R., Romano, S., & Venuta, S. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.017 · Cited by 138
Straume, O., & Akslen, L. A. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64922-x · Cited by 135
The GIST paradigm: lessons for other kinase‐driven cancers
Antonescu, C. R. (2010) · The Journal of Pathology · doi:10.1002/path.2798 · Cited by 133
Dannull, J., Nair, S. K., Su, Z. Z., Boczkowski, D., DeBeck, C., Yang, B. K., Gilboa, E., & Vieweg, J. (2004) · Blood · doi:10.1182/blood-2004-10-3944 · Cited by 133
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH
Jönsson, G. B., Dahl, C., Staaf, J., Sandberg, T., Bendahl, P.-O., Ringnér, M., Guldberg, P., & Borg, Å. (2007) · Oncogene · doi:10.1038/sj.onc.1210252 · Cited by 132
Dummer, R., Robert, C., Chapman, P. B., Sosman, J. A., Middleton, M. R., Bastholt, L., Kemsley, K., Cantarini, M., Morris, C., & Kirkwood, J. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9033 · Cited by 132
Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases
Kraehn, G., Utikal, J. S., Udart, M., Greulich, K. M., Bezold, G., Kaskel, P., Leiter, U., & Peter, R. U. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1535 · Cited by 128
Frequent p16-Independent Inactivation of p14ARF in Human Melanoma
Freedberg, D. E., Rigas, S. H., Russak, J. E., Gai, W., Kaplow, M., Osman, I., Turner, F., Randerson‐Moor, J. A., Houghton, A. N., BUSAM, K. J., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn157 · Cited by 125
Cytolytic T‐cell responses of cancer patients vaccinated with a MAGE antigen
Coulie, P. G., Karanikas, V., Lurquin, C., Colau, D., Connerotte, T., Hanagiri, T., Pel, A. V., Lucas, S., Godelaine, D., Lonchay, C., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18804.x · Cited by 124
Fay, J. W., Palucka, K., Paczesny, S., Dhodapkar, M. V., Johnston, D. A., Burkeholder, S. B., Ueno, H., & Banchereau, J. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0106-6 · Cited by 123
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.
Infante, J. R., Fecher, L. A., Nallapareddy, S., Gordon, M. S., Flaherty, K. T., Cox, D. S., DeMarini, D. J., Morris, S. R., Burris, H. A., & Messersmith, W. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2503 · Cited by 121
Self-citationAn Oncogenic Role for ETV1 in Melanoma
Jané-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3092 · Cited by 115
Self-citationMolhoek, K. R., Brautigan, D. L., & Slingluff, C. L. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-39 · Cited by 115
Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
Smalley, K. S. M., Contractor, R., Nguyen, T. K., Xiao, M., Edwards, R. H., Muthusamy, V., King, A. J., Flaherty, K. T., Bosenberg, M., Herlyn, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0235 · Cited by 115
Self-citationReed, J. A., McNutt, N. S., Prieto, V. G., & Albino, A. P. (1994) · PubMed Central · Cited by 110
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
Eskandarpour, M., Kiaii, S., Zhu, C., Castro, J., Sakko, A. J., & Hansson, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20873 · Cited by 110
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
Yokoyama, S., Feige, E., Poling, L. L., Levy, C., Widlund, H. R., Khaled, M., Kung, A. L., & Fisher, D. E. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00480.x · Cited by 102
Self-citationCorominas, M., Kamino, H., León, J., & Pellicer, À. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6372 · Cited by 95
Schwartz, G. K., Robertson, S., Shen, A., Wang, E., Pace, L., Dials, H. J., Mendelson, D. S., Shannon, P., & Gordon, M. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3513 · Cited by 95
Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
the Cancer and Leukemia Group B, Gajewski, T. F., Salama, A. K. S., Niedzwiecki, D., Johnson, J. E., Linette, G. P., Bucher, C. J., Blaskovich, M. A., Sebti, S. M., & Haluska, F. G. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-246 · Cited by 89
LoRusso, P. M., Krishnamurthi, S., Rinehart, J. J., Nabell, L., Croghan, G. A., Varterasian, M. L., Sadis, S., Menon, S. S., Leopold, J., & Meyer, M. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3011 · Cited by 89
Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells.
Yuasa, Y., Gol, R., Chang, A. E., Chiu, I., Reddy, E. P., Tronick, S. R., & Aaronson, S. A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.12.3670 · Cited by 86
Barnhill, R. L., Xiao, M., Graves, D. T., & Antoniades, H. N. (1996) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1996.d01-1092.x · Cited by 85
Yao, K., Gietema, J. A., Shida, S., Selvakumaran, M., Fonrose, X., Haas, N. B., Testa, J., & O'Dwyer, P. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602864 · Cited by 82
Hauschild, A., Trefzer, U., Garbe, C., Kaehler, K. C., Ugurel, S., Kiecker, F., Eigentler, T., Krissel, H., Schott, A., & Schadendorf, D. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e328307c248 · Cited by 80
DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy
Schultze, J. L., Grabbe, S., & von-Bergwelt-Baildon, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.016 · Cited by 75
Recurrent Patterns of Dual RB and p53 Pathway Inactivation in Melanoma
Yang, G., Rajadurai, A., & Tsao, H. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23931.x · Cited by 73
Cai, G., Karni, A., de Oliveira, E. M. L., Weiner, H. L., Hafler, D. A., & Freeman, G. J. (2004) · Cellular Immunology · doi:10.1016/j.cellimm.2004.09.004 · Cited by 71
New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells
Kwon, B., Lee, H. W., & Kwon, B. S. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02263-9 · Cited by 63
New tumor antigens recognized by T cells
den Eynde, B. J. V., & Brichard, V. G. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80076-x · Cited by 62
Moore, S. R., Persons, D. L., Sosman, J. A., Bobadilla, D., Bedell, V., Smith, D. D., Wolman, S. R., Tuthill, R. J., Moon, J., Sondak, V. K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4068 · Cited by 52
Flaherty, K. T., Redlinger, M., Schuchter, L. M., Lathia, C. D., Weber, B., & O'Dwyer, P. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3037 · Cited by 50
Self-citationMachiels, J., van Baren, N., & Marchand, M. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.35244 · Cited by 49
Thallinger, C., Werzowa, J. M., Poeppl, W., Kovar, F. M., Pratscher, B., Valent, P., Quehenberger, P., & Joukhadar, C. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700872 · Cited by 35
CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy
Keilholz, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4fe · Cited by 33
Stevens, C. W., Manoharan, T. H., & Fahl, W. E. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.3875 · Cited by 32
Wang, Y., & Becker, D. (1996) · PubMed · Cited by 31
Vonderheide, R. H., & June, C. H. (2003) · Immunologic Research · doi:10.1385/ir:27:2-3:341 · Cited by 31
Rotolo, S., Diotti, R., Gordon, R. E., Qiao, R., Yao, Z., Phelps, R. G., & Dong, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20865 · Cited by 28
A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
O'Dwyer, P. J., LoRusso, P. M., DeMichele, A., Gupta, V., Barbi, A., Dials, H. J., Chen, I., Courtney, R., Wilner, K. D., & Schwartz, G. K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3550 · Cited by 20
Venetsanakos, E., Stuart, D. D., Tân, N. D., Ye, H., Salangsang, F., Aardalen, K., Faure, M., Heise, C. C., Mendel, D. B., & Jallal, B. (2006) · Cancer Research · Cited by 14
Review : Dendritic Cell-Based Vaccine in the Treatment of Patients with Advanced Melanoma
Zhang, S., Wang, Q., & Miao, B. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2007.354 · Cited by 12
Immunological detection of altered signaling molecules involved in melanoma development
Kawakami, Y., Sumimoto, H., Fujita, T., & Matsuzaki, Y. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1583-y · Cited by 10
Cited by
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Signaling Pathways in Melanogenesis
D’Mello, S., Finlay, G., Baguley, B., & Askarian-Amiri, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071144 · Cited by 1,071
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
Bresnick, A. R., Weber, D. J., & Zimmer, D. B. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3893 · Cited by 822
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Metadata
- Authors
- Flaherty, K. T., Hodi, F. S., & Fisher, D. E.
- Venue
- Nature Reviews Cancer
- Published
- 2012-04-05
- Volume
- 12
- Issue
- 5
- Pages
- 349-361
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2020543365
- Cited by
- 354
- References
- 181
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.